Provided by Tiger Trade Technology Pte. Ltd.

IGC Pharma

0.3080
+0.030811.11%
Post-market: 0.3001-0.0079-2.56%19:50 EDT
Volume:1.87M
Turnover:553.46K
Market Cap:31.84M
PE:-3.95
High:0.3100
Open:0.2875
Low:0.2787
Close:0.2772
52wk High:0.4985
52wk Low:0.2350
Shares:103.38M
Float Shares:90.33M
Volume Ratio:1.95
T/O Rate:2.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0780
EPS(LYR):-0.0931
ROE:-83.34%
ROA:-50.31%
PB:3.94
PE(LYR):-3.31

Loading ...

IGC Pharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $265.000K Beat $258.000K Estimate

Benzinga Earnings
·
Aug 17

IGC Pharma Q2 FY26 Net Loss Widens to $3 Million; Revenue Falls to $265,000

Reuters
·
Aug 17

IGC Pharma Expands Regulatory, AI Data Science Capabilities Ahead of Phase 2 CALMA Readout

Reuters
·
Aug 11

IGC Pharma evaluates potential civil remedies following federal jury verdict

TIPRANKS
·
Jul 29

IGC Pharma Weighs Civil Claims After Andrew Left Securities Fraud Conviction Tied to 2018 Short Campaign

Reuters
·
Jul 29

IGC Pharma Executives Convert Debt Into Equity Shares

TIPRANKS
·
Jul 07

IGC Pharma Sells 4,274,853 Shares to CEO, CFO at $0.27 in Unregistered Placement

Reuters
·
Jul 07

IGC Pharma announced beta version of Agentic Harmonization Assistant

TIPRANKS
·
Jun 24

IGC Pharma plans AHA platform showcase at Alzheimer’s Association International Conference 2026

Reuters
·
Jun 23

IGC Pharma hits 146-patient enrollment target in Phase 2 CALMA trial for Alzheimer’s agitation drug IGC-AD1

Reuters
·
Jun 11

Ascendiant Capital Markets lifts IGC Pharma price target to $5.5

Reuters
·
Jun 09

IGC Pharma Extends and Amends $12 Million Loan Facility

TIPRANKS
·
Jun 09

IGC Pharma extends O-Bank loan facility, keeps USD 12 million limit

Reuters
·
Jun 09

IGC Pharma Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Jun 08

IGC Pharma adds Mount Sinai clinical site as CALMA trial advances

TIPRANKS
·
Jun 02

IGC Pharma adds Mount Sinai as clinical site for Phase 2 CALMA trial of IGC-AD1 in Alzheimer’s agitation

Reuters
·
Jun 02

IGC Pharma FY26 Q1 net loss widens to $2.4 million; revenue slips to $317,000

Reuters
·
May 21

Top News Today: Stocks Slide, Treasury Yields Rise on Strait, Inflation Fears

Dow Jones
·
May 16

IGC Pharma Q1 FY26 net loss widens 101% to $2.4 million; revenue falls 4% to $317,000

Reuters
·
May 16

IGC Pharma to present new Tau-PET biomarker research at Global Tau conference

TIPRANKS
·
May 15